Mike Gladstone, global president and general manager of Pfizer Inflammation and Immunology unit, said that the acquisition of Arena is in line with the company’s capabilities and expertise in immunology and inflammatory-related conditions. Over the years, Pfizer has successfully created an innovation engine that develops potential medicines for patients worldwide with chronic and debilitating immuno-inflammatory conditions. The company understands that there is an urgent need to look into other treatment options with high potential, which is where Arena’s cannabinoid-drug pipeline comes in.
